Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial

Disclosures

BS and CLB were employed by Bristol Myers Squibb at the time the study was conducted. AHW has served on advisory boards for AbbVie, Agios, Amgen, Celgene/Bristol Myers Squibb, Gilead, Janssen, MacroGenics, Novartis, Pfizer, Roche, and Servier; has received research funding to his institution from AbbVie, Amgen, AstraZeneca, Celgene/Bristol Myers Squibb, Novartis, and Servier; has served on a speakers bureau for AbbVie, Celgene, and Novartis; and is eligible for royalty payments from the Walter and Eliza Hall Institute of Medical Research related to venetoclax. GJR reports receiving research support from Janssen and has served in an advisory position for AbbVie, Agios, Amgen, Astellas, AstraZeneca, Bluebird Bio, Blueprint Medicines, Bristol Myers Squibb, Catamaran, Celgene, Glaxo SmithKline, Helsinn, Janssen, Jasper Therapeutics, Jazz Pharmaceuticals, Mesoblast, Novartis, Pfizer, Roche, Syndax, and Takeda (IRC Chair). HDo reports receiving honoraria from Incyte and Servier. HDö has served in a consultancy position for AbbVie, Agios, Amgen, Astellas, Berlin-Chemie, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Janssen, Jazz Pharmaceuticals, Novartis, Servier, and Syndax; reports receiving research funding from AbbVie, Agios, Amgen, Astellas, Bristol Myers Squibb, Jazz Pharmaceuticals, Kronos Bio, Novartis, and Pfizer; and reports receiving honoraria from AbbVie, Agios, Amgen, Astellas, AstraZeneca, Berlin-Chemie, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Janssen, Jazz Pharmaceuticals, Novartis, Servier, and Syndax. ACS has served on an advisory committee for AbbVie, Agios, Amgen, Astellas, Bristol Myers Squibb, Jazz, Pfizer, Teva, and Servier; reports receiving research funding from AbbVie, Agios, Amgen, Astellas, Bristol Myers Squibb, GlycoMimetics, Kite/Gilead, Pfizer, and Servier; and reports receiving honoraria from AbbVie, Agios, Amgen, Astellas, Bristol Myers Squibb, Pfizer, Teva, and Servier. PM has served in a consultancy position for Menarini/Stemline, Gilead, Otsuka, Kura Oncology, AbbVie, Bristol Myers Squibb, Novartis, Jazz Pharmaceuticals, BeiGene, Astellas, Pfizer, Incyte, Takeda, Ryvu, and Nerviano; reports receiving research funding from AbbVie, Bristol Myers Squibb, Jazz Pharmaceuticals, Menarini/Stemline, Novartis, Pfizer, and Takeda; and has served on a speakers bureau for AbbVie, Astellas, Bristol Myers Squibb, Gilead, Jazz Pharmaceuticals, and Pfizer. DS reports receiving grants or contracts, honoraria, consulting fees, and travel support from AbbVie, Bristol Myers Squibb, Novartis, and Pfizer; and has served in a leadership role for the Belgian College for Reimbursement of Orphan Drugs. TP reports employment and stock ownership with Bristol Myers Squibb. YL reports employment with Bristol Myers Squibb and Eli Lilly stock ownership. BS reports prior employment with Celgene/Bristol Myers Squibb. CLB reports prior employment and stock ownership with Bristol Myers Squibb. FR reports receiving research funding from Amgen, Astellas, Astex/Taiho, Biomea Fusion, Celgene/Bristol Myers Squibb, Prelude, Syros, and Xencor; and honoraria from AbbVie, Astellas, AstraZeneca, Celgene/Bristol Myers Squibb, Novartis, and Syros. AstraZeneca, Celgene/Bristol Myers Squibb, Novartis, and Syros.

Contributions

The sponsors collected and analyzed data in conjunction with all authors. AHW wrote the first draft of the manuscript. All authors revised the manuscript and reviewed and approved the final version for submission.

Data-sharing statement

Bristol Myers Squibb policy on data sharing may be found at https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html.